Viyash Scientific Limited (IN:VIYASH)
:VIYASH
Want to see IN:VIYASH full AI Analyst Report?
Top Page
Viyash Scientific
(VIYASH)
Select Model
Select Model
Rating:65Neutral
Price Target:
₹271.00
▲(28.65% Upside)
Action:Reiterated
Date:05/21/26
The score is driven mainly by improved financial performance (sharp 2026 growth, stronger profitability, and reduced leverage). Technicals are supportive but appear overbought, while valuation is the key headwind due to the very high P/E and lack of dividend support.
Positive Factors
Revenue and margin rebound
Revenue more than doubled in 2026 while operating margins rose to roughly 12% EBIT and 19% EBITDA. This demonstrates the business can scale profitably across a larger base, supporting more durable cash generation and reinvestment capacity if the trend holds beyond a single year.
Negative Factors
Historic earnings volatility
The firm experienced losses in 2023–2024 and material volatility across 2022–2025, indicating execution and demand risk. Such a history weakens predictability of future cash flows and means management must prove sustained, repeatable profitability before earnings are deemed durable.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and margin rebound
Revenue more than doubled in 2026 while operating margins rose to roughly 12% EBIT and 19% EBITDA. This demonstrates the business can scale profitably across a larger base, supporting more durable cash generation and reinvestment capacity if the trend holds beyond a single year.
Read all positive factors
Viyash Scientific (VIYASH) vs. iShares MSCI India ETF (INDA)
Market Cap
₹110.03B
Dividend YieldN/A
Average Volume (3M)119.95K
Price to Earnings (P/E)44.7
Beta (1Y)1.33
Revenue Growth70.42%
EPS Growth270.62%
CountryIN
Employees1,244
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.67
Shares Outstanding436,875,500
10 Day Avg. Volume209,903
30 Day Avg. Volume119,946
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.72
Price to Sales (P/S)2.32
P/FCF Ratio61.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)9.3
Revenue Forecast (FY)₹38.63B
Viyash Scientific Business Overview & Revenue Model
Company Description
Viyash Scientific Limited operates in the veterinary healthcare business in Europe, Asia, and internationally. The company provides finished dosage formulation in therapeutic areas, such as nutrition, pain management, parasite control, antibiotics...
How the Company Makes Money
null...
Viyash Scientific Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
78
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 16.58B | 34.20B | 15.51B | 13.66B | 14.18B | 14.10B |
| Gross Profit | 8.08B | 10.58B | 7.40B | 5.53B | 1.59B | 5.66B |
| EBITDA | 1.97B | 6.54B | 1.59B | 549.80M | -464.48M | 1.18B |
| Net Income | 418.10M | 1.77B | 218.80M | -358.69M | -1.21B | 409.55M |
Balance Sheet | ||||||
| Total Assets | 17.26B | 46.28B | 16.02B | 15.40B | 15.29B | 14.51B |
| Cash, Cash Equivalents and Short-Term Investments | 722.20M | 2.70B | 632.04M | 687.85M | 416.25M | 591.21M |
| Total Debt | 4.90B | 4.90B | 4.81B | 4.88B | 4.44B | 3.65B |
| Total Liabilities | 8.40B | 15.14B | 8.32B | 8.27B | 7.80B | 7.11B |
| Stockholders Equity | 8.09B | 29.11B | 7.04B | 6.57B | 6.99B | 6.92B |
Cash Flow | ||||||
| Free Cash Flow | 288.00M | 1.29B | 442.70M | -2.12M | -693.71M | -18.69M |
| Operating Cash Flow | 449.00M | 2.64B | 833.60M | 305.95M | 168.08M | 305.95M |
| Investing Cash Flow | -42.20M | -938.90M | -247.80M | -119.05M | -649.58M | -955.66M |
| Financing Cash Flow | -325.70M | -543.10M | -607.30M | 45.46M | 322.28M | 672.57M |
Viyash Scientific Technical Analysis
Positive
210.65
Price Trends
206.32
Positive
207.28
Positive
203.43
Positive
Market Momentum
9.44
Negative
68.45
Neutral
67.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VIYASH, the sentiment is Positive. The current price of 210.65 is below the 20-day moving average (MA) of 219.45, above the 50-day MA of 206.32, and above the 200-day MA of 203.43, indicating a bullish trend. The MACD of 9.44 indicates Negative momentum. The RSI at 68.45 is Neutral, neither overbought nor oversold. The STOCH value of 67.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:VIYASH.
Viyash Scientific Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | ₹153.26B | 17.84 | ― | 0.31% | 12.89% | 19.55% | |
74 Outperform | ₹130.03B | 21.18 | ― | 0.56% | 6.91% | 16.04% | |
74 Outperform | ₹105.27B | 15.54 | ― | 0.41% | 4.88% | 66.43% | |
68 Neutral | ₹80.94B | 27.96 | ― | ― | 5.85% | -25.45% | |
65 Neutral | ₹110.03B | 44.70 | ― | ― | 70.42% | 270.62% | |
62 Neutral | ₹147.95B | 19.32 | ― | 1.28% | 10.08% | 15.65% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:VIYASH
Viyash Scientific
247.75
67.85
37.72%
IN:AKUMS
Akums Drugs and Pharmaceuticals Limited
521.10
-43.05
-7.63%
IN:APLLTD
Alembic Pharmaceuticals Limited
747.65
-214.24
-22.27%
IN:CAPLIPOINT
Caplin Point Laboratories Limited
2,022.45
-255.97
-11.23%
IN:ALIVUS
Glenmark Life Sciences Limited
1,055.65
-41.31
-3.77%
IN:STAR
Strides Pharma Science Ltd
1,158.90
431.83
59.39%
Viyash Scientific Corporate Events
Viyash Scientific Secures ICRA AA- Rating for Rs. 185 Crore Working Capital
Apr 22, 2026
Viyash Scientific Limited announced that ICRA Limited has assigned a long-term credit rating of [ICRA]AA- with a Stable outlook to its fund-based working capital facilities totaling Rs. 185 crore. The new ICRA rating marks an improvement over the ...
Viyash Scientific Adds Carlyle Nominees to Board, Trims ESOP Pool
Apr 22, 2026
Viyash Scientific Limited has reshaped its board by appointing Amit Jain and Abhiroop Jayanthi, both representatives of the Carlyle group, as additional non-executive, non-independent directors, subject to shareholder approval. The move underscore...
Viyash Scientific Adds Carlyle Nominees to Board and Trims ESOP Pool
Apr 22, 2026
Viyash Scientific Limited’s board has appointed Amit Jain and Abhiroop Jayanthi as additional non-executive, non-independent directors, both representing Carlyle, effective April 22, 2026, subject to shareholder approval. The move strengthen...
Viyash Scientific Allots Shares Under Employee Stock Option Plan
Apr 2, 2026
Viyash Scientific Limited has approved the allotment of 16,667 fully paid equity shares to eligible employees upon exercise of options under its SeQuent ESOP 2020 at an exercise price of Rs. 86 per share. Following this issuance, the company’...
Viyash Scientific Shuts Trading Window Ahead of FY26 Results
Mar 30, 2026
Viyash Scientific Limited has announced the closure of its trading window for designated persons and their immediate relatives, in line with SEBI’s Prohibition of Insider Trading Regulations and the company’s own code of conduct. The w...
Viyash Scientific Secures Shareholder Approval for New Leadership and ESOP Grant
Mar 13, 2026
Viyash Scientific Limited has announced that shareholders have approved, via remote e-voting through a postal ballot, several key management appointments and compensation matters, including the appointment and remuneration of Dr. Haribabu Bodepudi...
Viyash Scientific Allots Shares Under ESOP, Slightly Increases Equity Base
Feb 23, 2026
Viyash Scientific Limited has approved the allotment of 113,001 fully paid equity shares with a face value of Rs. 2 each to eligible employees under its SeQuent ESOP 2020 at an exercise price of Rs. 86 per share. Following this allotment, the comp...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.